Recombinant multi-species CLEC14A/EGFR5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CLEC14A/EGFR5 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. Members of this family share a common protein fold and have diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response. This family member plays a role in cell-cell adhesion and angiogenesis. It functions in filopodia formation, cell migration and tube formation. Due to its presence at higher levels in tumor endothelium than in normal tissue endothelium, it is considered to be a candidate for tumor vascular targeting. [provided by RefSeq, Jan 2012]
The Alternative Names of target: CLEC14A, EGFR5,C-type lectin domain family 14 member A,Epidermal growth factor receptor 5 (EGFR-5),CEG1,EGFR-5,C14orf27

Target products collectionGo to CLEC14A/EGFR5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0265-Ab-1/ GM-Tg-hg-IP0265-Ab-2 Human CLEC14A/EGFR5 protein Human
GM-Tg-rg-IP0265-Ab-1/ GM-Tg-rg-IP0265-Ab-2 Rat CLEC14A/EGFR5 protein Rat
GM-Tg-mg-IP0265-Ab-1/ GM-Tg-mg-IP0265-Ab-2 Mouse CLEC14A/EGFR5 protein Mouse
GM-Tg-cynog-IP0265-Ab-1/ GM-Tg-cynog-IP0265-Ab-2 Cynomolgus/Rhesus macaque CLEC14A/EGFR5 monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0265-Ab-1/ GM-Tg-felg-IP0265-Ab-2 Feline CLEC14A/EGFR5 protein Feline
GM-Tg-cang-IP0265-Ab-1/ GM-Tg-cang-IP0265-Ab-2 Canine CLEC14A/EGFR5 protein Canine
GM-Tg-bovg-IP0265-Ab-1/ GM-Tg-bovg-IP0265-Ab-2 Bovine CLEC14A/EGFR5 protein Bovine
GM-Tg-equg-IP0265-Ab-1/ GM-Tg-equg-IP0265-Ab-2 Equine CLEC14A/EGFR5 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0265-Ab-1/ GM-Tg-hg-IP0265-Ab-2; GM-Tg-rg-IP0265-Ab-1/ GM-Tg-rg-IP0265-Ab-2;
GM-Tg-mg-IP0265-Ab-1/ GM-Tg-mg-IP0265-Ab-2; GM-Tg-cynog-IP0265-Ab-1/ GM-Tg-cynog-IP0265-Ab-2;
GM-Tg-felg-IP0265-Ab-1/ GM-Tg-felg-IP0265-Ab-2; GM-Tg-cang-IP0265-Ab-1/ GM-Tg-cang-IP0265-Ab-2;
GM-Tg-bovg-IP0265-Ab-1/ GM-Tg-bovg-IP0265-Ab-2; GM-Tg-equg-IP0265-Ab-1/ GM-Tg-equg-IP0265-Ab-2
Products Name CLEC14A/EGFR5 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name CLEC14A/EGFR5
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CLEC14A/EGFR5 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.